Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People coinfected with both HIV and HBV are much more likely to develop mild kidney problems after starting tenofovir
Study suggests the integrase inhibitor Isentress (raltegravir) could prevent the accumulation of excess fat in the liver (steatosis)
An experimental therapeutic vaccine improved hepatitis C cure rates by 12 percent in patients with a hard-to-treat subtype of the virus who di...
About 12 percent of HIV-positive people with chronic hepatitis B virus (HBV) infection failed to control their HBV after one year with Viread...
Boceprevir, Merck?s experimental hepatitis C virus (HCV) protease inhibitor, greatly improves cure rates, sustained virologic responses (SVRs)...
Three-year survival rates after a diagnosis of hepatocellular carcinoma (liver cancer) are similar between people living with HIV and HIV-nega...
Combining Vertex Pharmaceuticals’ experimental HCV protease inhibitor telaprevir with pegylated interferon and ribavirin for the first...
Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center have reached an early, but important,...
People who fail to respond rapidly to HCV treatment are more likely to achieve a cure if they extend their treatment by at least six months.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.